Metronidazole

Related products

• 

  Crohn's disease

  BCG

  【Product name】IMMUCYST, Immunobladder, TICE BCG

  [English common name]Bacillus Calmette-Guerin vaccine

  [Chinese common name]BCG

  [English name]

  [Chinese other name]

  [Indications] This product (BCG immunotherapeutic agent) is suitable for intravesical use and treatment of primary recurrent carcinoma in situ (CIS) of the bladder to reduce the frequency of tumor recurrence. It is indicated for the treatment of carcinoma in situ with or without papillary tumors. However, it is not suitable for the treatment of papilloma that occurs alone. This product is also used as a remedy for the bladder to respond to other in situ carcinoma (CIS) treatments. Treatment and prevention of primary or recurrent carcinoma in situ or superficial papilloma after transurethral resection (TA and T1).

  [Usage and Dosage] Intravesical treatment and prevention of bladder carcinoma in situ (CIS) should be started 7 to 14 days after biopsy or transurethral resection. In a single dose of 3 vials, this product (BCG immunotherapeutic agent) was administered by intravesical injection once a week for 6 weeks (induction therapy). Each dose (3 bottles of prepared vials) was diluted with 50 ml of bacteria and diluted with preservative-free saline to a total of 53 ml. The urethral catheter is inserted into the bladder under aseptic conditions, guiding the contents of the bladder, and then slowly injecting 50 ml of the suspension of the product by gravity, and then taking out the catheter. During the first hour after perfusion, the patient should be placed in the prone, lying down and lying on the left and right sides for 15 minutes. The patient can then stand but maintain the suspension for 60 minutes for a total of 2 hours. It should be taught to urinate if needed for less time. . At the end of the 2 hours, all patients urinate in a sitting position for safety reasons. Patients should be taught to maintain adequate water. The true number of perfusions required to achieve the optimal response is still unknown. Most responding patients are achieved with 6 to 12 perfusions.

  [Storage] The medicine should be placed in a refrigerator of 2 to 8 degrees Celsius (not frozen); if it deteriorates or expires, it can no longer be used.

  [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.
• 

  Crohn's disease , Optic neuromyelitis

  Methylprednisolone

  【Product name】Medrol

  [English common name]Methylprednisolone

  [Chinese common name]Methylprednisolone

  [English name]Methylprednisolone, A-Methapred, Adlone-40, Adlone-80

  [Chinese other name]A strong dragon, 6a-methylprednisolone, methylprednisolone, methylprednisolone

  [Indications] Mainly used for indications of allergic and autoimmune inflammatory diseases.

  【Dosage】
  1. According to the treatment needs of different diseases, the initial dose of methylprednisolone tablets can be adjusted between 4mg and 48mg of methylprednisolone per day.
  (1) Patients with mild symptoms usually receive a lower dose; some patients may require a higher initial dose.
  (2) Diseases that are clinically required to be treated with higher doses include multiple sclerosis (200 mg/day), cerebral edema (200-1000 mg/day), and organ transplantation (up to 7 mg/kg/day).
  (3) If there is no satisfactory clinical effect after sufficient treatment for a period of time, the methylprednisolone tablet should be discontinued and other suitable treatment methods should be used.
  (4) If it is necessary to stop the drug after long-term treatment, it is recommended to reduce the amount by volume, and not to withdraw the drug suddenly.

  [Storage] sealed, stored at 15 ° C -25 ° C.

  [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.
• 

  Psoriatic arthritis (PsA) , Crohn's disease

  Utec monoclonal antibody

  【Product name】Stelara

  [English common name]Ustekinumab

  [Chinese common name]Utec monoclonal antibody

  [English name]

  [Chinese other name]

  [Indications] Stelara is a drug used to treat the following diseases:
  Moderate to severe plaque psoriasis (a disease that causes red, scaly plaque in the skin). It is used in adults and children over the age of 12, and its condition is unresponsive or cannot be treated with other systemic (systemic) psoriasis, such as cyclosporine, methotrexate or PUVA (psoralen UV A). PUVA is a treatment in which a patient receives a drug containing a compound called "psoralen" prior to exposure to ultraviolet light.
  Activity in adultsPsoriatic arthritis(Inflammation of the joints associated with psoriasis), when the condition is not adequately responsive to other treatments, is called anti-rheumatic drugs (DMARDs) that improve the disease. Stelara can be used alone or in combination with methotrexate (DMARD); moderate to severe activity in adultsCrohn's disease(a disease that causes intestinal inflammation), whose condition is poorly responsive to other Crohn's disease treatments or is unacceptable for such treatment.

  [Usage and Dosage] Adults aged 18 years and older started treatment with a loading dose of 320 mg delivered to two 2 ml, subcutaneously 160 mg on the same day at two different locations. Continue to use a weekly injection of 160 mg as a single, 2 ml, subcutaneously administered dose. Don't give ARCALYST more often than once a week. Pediatric patients are 12 to 17 years old: the starting dose for treatment is 4.4 mg/kg, up to 320 mg, delivered with one or two subcutaneous injections, with a maximum single injection volume of 2 mL. Continue to administer a weekly injection of 2.2 mg/kg, up to 160 mg, as a single subcutaneous injection, up to 2 ml. If the initial dose given is two injections, they should be on the same day at two different locations. Don't give ARCALYST more often than once a week.

  [Storage] Store in the refrigerator (2 ° C – 8 ° C). Do not freeze. Keep the vial in an outer carton to prevent light from shining.

  [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.
• 

  Uveitis , Crohn's disease

  Adalimumab

  【Product name】Humira

  [English common name]Adalimumab

  [Chinese common name]Adalimumab

  [English name]

  [Chinese other name]

  [Indications] This product is suitable forRheumatoid Arthritis:
  1. This product is combined with methotrexate for the treatment of adult patients with moderate to severe active rheumatoid arthritis who have changed their disease resistance to rheumatoid drugs (DMARDs), including methotrexate.
  2. This product can be used in combination with methotrexate to slow the progression of joint damage in patients (X-ray display) and improve physical function.

  [Usage and Dosage] The treatment of this product should be carried out under the supervision of a specialist with experience in the diagnosis and treatment of rheumatoid arthritis. For those patients who are considered appropriate by the treating physician and who can be followed up when necessary, they can be administered by themselves after receiving the correct injection technique training.
  1. Discontinuation of dosing, available data indicates that re-use of the product after 70 days or more intervals will achieve the same level of clinical response and safety as before discontinuation of dosing. For adults, for adults with rheumatoid arthritis, a recommended dose of 40 mg adalimumab is administered subcutaneously every 2 weeks. Methotrexate should continue to be used during the treatment of this product.

  [Storage] Sealed.

  [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.